iSpecimen Inc. (ISPC) vs ENDRA Life Sciences Inc. (NDRA)

iSpecimen Inc. and ENDRA Life Sciences Inc. are both Diagnostics & Research companies. ENDRA Life Sciences Inc. is the larger, with a market value of $8.9M against $3.1M — 2.8× the size. ENDRA Life Sciences Inc. has the higher net margin (0.00% vs −2,449.0%) and the lower return on invested capital (−539.9% vs 0.00%). Across the 15 metrics below, ENDRA Life Sciences Inc. leads on 10 and iSpecimen Inc. on 5.

Valuation

Metric ISPC NDRA Diagnostics & Research median
P/E n/m n/m 33.95
P/S 3.77 22.35 4.87
P/B 1.01 1.27 3.12
Price to free cash flow n/m n/m 34.02
EV/EBITDA 0.31 n/m 25.20
EV/Sales (5.55) 7.61 5.66
Earnings yield (4,479.37%) (104.64%) (1.75%)
Free cash flow yield (617.94%) (98.06%) (0.13%)

Profitability

Metric ISPC NDRA Diagnostics & Research median
Gross margin (108.26%) 0.00% 50.89%
Operating margin (2,020.05%) 0.00% (8.57%)
Net margin (2,449.02%) 0.00% (6.37%)
Free cash flow margin (1,866.61%) 0.00% 0.00%
Return on equity (968.44%) (152.04%) (2.92%)
Return on assets (170.09%) (110.08%) (6.71%)
Return on invested capital 0.00% (539.89%) 0.00%

Growth

Metric ISPC NDRA Diagnostics & Research median
Revenue growth (TTM) (92.11%) — 7.69%
EPS growth (last fiscal year) 87.03% 84.32% —
Revenue growth, 5-year CAGR (25.10%) — 7.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ISPC NDRA Diagnostics & Research median
Debt to equity 0.00 0.00 0.11
Current ratio 0.82 7.10 2.02
Net debt to EBITDA 0.95 0.14 0.78

Dividend

Metric ISPC NDRA Diagnostics & Research median
Dividend yield — — 0.70%
Payout ratio 0.00 0.00 0.00

Size

Metric ISPC NDRA Diagnostics & Research median
Market cap 3.12m 8.89m 2.56b

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack